xCures, a healthcare data company using artificial intelligence to structure fragmented medical records, has successfully closed a $46 million Series B funding round. The financing was led by Innovius Capital and elevates the company's total capital raised to over $76 million, with a post-money valuation of $127 million. This new investment will fuel the expansion of its platform, which aims to transform complex patient data into actionable clinical intelligence for providers.
From Patient Support to Data Infrastructure
Founded in 2018 as a spinout from Cancer Commons, xCures initially focused on providing decision-support tools for patients with advanced cancer. While working directly with patients, the company discovered a significant systemic bottleneck in accessing and utilizing their medical information. This challenge, with records arriving via fax and FedEx, prompted a strategic pivot toward building the foundational infrastructure to manage healthcare's "dirty data."
Engineering Clinical Clarity
The company's core solution is the xCures Clinical Clarity Engine, designed to address the issue of unstructured and error-prone medical records. CEO Mika Newton explains that unlike competitors focused on data transport, their platform creates genuine clinical intelligence from disorganized information. The engine integrates various capabilities to generate decision-ready checklists and automated patient histories, all backed by evidence-grade data for reliability.
To manage this complex task efficiently, xCures employs a combination of proprietary machine learning models and commercial AI tools under a strict governance framework. This advanced technological approach has enabled the company to process over 300 million medical records from more than 550,000 healthcare locations nationwide. The platform's ability to deliver structured insights at scale supports clinical decisions for millions of patients across the United States.
Accelerating Growth and Market Adoption
This innovative approach has translated into substantial commercial success and rapid growth for the company. xCures saw its annualized recurring revenue grow from approximately $3 million to $10 million in 2025 and is on track to exceed $20 million in 2026. While the company achieved cash-flow breakeven last year, it is now strategically investing its new capital to expand its team and meet future demand.
The platform has gained significant traction among enterprise clients, with a customer base of 25 organizations including diagnostic leaders like Exact Sciences and Caris Life Sciences. Large hospital networks utilize the tool to generate instant patient histories for surgical planning, while telehealth providers and Medicare Advantage plans use it to automate administrative tasks. This broad adoption demonstrates the engine's versatility in solving critical industry-wide problems.
Investor Confidence in a Foundational Platform
The Series B round underscores strong investor confidence in the company's vision and execution. Stu Posluns, a partner at lead investor Innovius Capital, praised xCures for its unique ability to locate, extract, and normalize messy data from thousands of incompatible sources. He noted that the team is successfully building the foundational AI data layer that will power the entire healthcare industry by applying real clinical context.
The successful $46 million financing round positions xCures to significantly accelerate its mission of bringing clarity to the complex world of healthcare data. By focusing on turning fragmented records into actionable intelligence, the company is poised to reduce administrative burdens and improve efficiency for providers and patients alike. As the industry increasingly relies on AI, xCures is establishing itself as a critical player in building the infrastructure for a more data-driven future in medicine.